EP08.02. Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC? - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Michael MacManus
Meta Tag
Speaker Michael MacManus
Topic Local-Regional NSCLC: Multimodality Therapy
stage III non-small-cell lung cancer
concurrent chemoradiotherapy
adjuvant durvalumab
immunotherapy drug
definitive CRT
early treatment cessation
risk factors
multimodality therapy
adjuvant therapies
Powered By